Galectin Therapeutics Inc.
Galectin Therapeutics is a biopharmaceutical company developing therapies for fibrotic, cancer, and other diseases. Belapectin (GR-MD-02) is its lead product candidate, currently in Phase 2b/3 trials for NASH cirrhosis and liver fibrosis, as well as other indications.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
Indicator | Value |
---|
PER | 100.0 |
EV/EBITDA | 100.0 |
Price/Free Cash Flow' | 100.0 |
ROIC | -% |
Net Debt/EBITDA | 100.0 |